Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Transcript (slightly edited)
What incentives will be necessary for physicians to take on 2-sided risk?
I think there will really have to be some detailed and not as much guarantees, but some really clear metrics, so that they know that they will be achievable in order for the physicians to take 2-sided risk. I think a lot of those are surrounding making sure that we’re all on the same page with accurately measuring quality and what that means to a patient. So some of those could be financial incentives or ensuring that we’re in compliance with certain measure that the physician feels that is really going to drive quality for the oncology patients. You know, making sure that the totality of the patient Is really well defined versus just what’s happening in the clinic at the oncology office.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More